Analyst upgrade puts Oscar Health back in focus

Raymond James recently upgraded Oscar Health (OSCR) to Outperform after previously rating the stock at Market Perform. The firm pointed to potential margin expansion as the Affordable Care Act exchange market stabilizes and administrative efficiency improves.

At a share price of US$13.00, Oscar Health has had a mixed run, with a 30 day share price return of 0.93% contrasted with a 90 day share price decline of 21.83%, while the three year total shareholder return is very large at about 3x even after a five year total shareholder return decline of 58.91%. This suggests long term holders have seen big swings and recent momentum has cooled despite the Raymond James upgrade.

If this latest move has you thinking about where growth stories might emerge next, it could be a good time to scan 34 healthcare AI stocks for fresh healthcare technology ideas.

With Oscar Health now trading at US$13.00 and sitting at roughly an 18% discount to the US$15.40 analyst price target, you have to ask: is this a genuine mispricing, or is the market already baking in the margin story?

Most Popular Narrative: 18% Undervalued

With Oscar Health last closing at $13.00 against a most followed fair value of about $15.78, the prevailing narrative sees meaningful upside anchored in execution on pricing, margins and product expansion.

Analysts have nudged their fair value estimate for Oscar Health higher to about $15.78 from $15.22, citing updated work on pricing and benefit design, exchange enrollment resilience despite subsidy changes, and expectations for a slightly richer future P/E multiple.

Curious what kind of revenue growth, margin lift and earnings power need to fall into place to support that higher fair value? The full narrative lays out a detailed path that leans on pricing discipline, Florida expansion and tighter cost control, backed by specific profit and valuation assumptions that go well beyond a simple price target.

Result: Fair Value of $15.78 (UNDERVALUED)

However, you still need to weigh policy and regulatory shifts that could pressure claims costs and margins, as well as the risk that industry consolidation may limit cost advantages.

Next Steps

If this mix of optimism and caution feels familiar, do not wait on others to decide the story for you. Instead, check the 2 key rewards and 1 important warning sign and weigh it against your own expectations.

Looking for more investment ideas?

If Oscar Health has sharpened your thinking, do not stop here. The next move could be spotting another opportunity before it hits everyone else’s radar.

• Spot potential mispricings early by scanning 48 high quality undervalued stocks that pair solid fundamentals with price tags that may not fully reflect their financial profile.
• Prioritise resilience by checking out 68 resilient stocks with low risk scores so you can focus on companies with steadier risk scores instead of constantly reacting to surprises.
• Hunt for underfollowed potential by reviewing our screener containing 25 high quality undiscovered gems that combine quality metrics with relatively low market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.